OBJECTIVE: To assess differences in access to antiretroviral treatment (ART) and patient outcomes across public sector treatment facilities in the Free State province, South Africa. DESIGN: Prospective cohort study with retrospective database linkage. We analysed data on patients enrolled in the treatment programme across 36 facilities between May 2004 and December 2007, and assessed percentage initiating ART and percentage dead at 1 year after enrolment. Multivariable logistic regression was used to estimate associations of facility-level and patient-level characteristics with both mortality and treatment status. RESULTS: Of 44 866 patients enrolled, 15 219 initiated treatment within 1 year; 8 778 died within 1 year, 7 286 before accessing ART. Outcomes at 1 year varied greatly across facilities and more variability was explained by facility-level factors than by patient-level factors. The odds of starting treatment within 1 year improved over calendar time. Patients enrolled in facilities with treatment initiation available on site had higher odds of starting treatment and lower odds of death at 1 year compared with those enrolled in facilities that did not offer treatment initiation. Patients were less likely to start treatment if they were male, severely immunosuppressed (CD4 count ≤50 cells/µl), or underweight (<50 kg). Men were also more likely to die in the first year after enrolment. CONCLUSIONS: Although increasing numbers of patients started ART between 2004 and 2007, many patients died before accessing ART. Patient outcomes could be improved by decentralisation of treatment services, fast-tracking the most immunodeficient patients and improving access, especially for men.
OBJECTIVE: To assess differences in access to antiretroviral treatment (ART) and patient outcomes across public sector treatment facilities in the Free State province, South Africa. DESIGN: Prospective cohort study with retrospective database linkage. We analysed data on patients enrolled in the treatment programme across 36 facilities between May 2004 and December 2007, and assessed percentage initiating ART and percentage dead at 1 year after enrolment. Multivariable logistic regression was used to estimate associations of facility-level and patient-level characteristics with both mortality and treatment status. RESULTS: Of 44 866 patients enrolled, 15 219 initiated treatment within 1 year; 8 778 died within 1 year, 7 286 before accessing ART. Outcomes at 1 year varied greatly across facilities and more variability was explained by facility-level factors than by patient-level factors. The odds of starting treatment within 1 year improved over calendar time. Patients enrolled in facilities with treatment initiation available on site had higher odds of starting treatment and lower odds of death at 1 year compared with those enrolled in facilities that did not offer treatment initiation. Patients were less likely to start treatment if they were male, severely immunosuppressed (CD4 count ≤50 cells/µl), or underweight (<50 kg). Men were also more likely to die in the first year after enrolment. CONCLUSIONS: Although increasing numbers of patients started ART between 2004 and 2007, many patients died before accessing ART. Patient outcomes could be improved by decentralisation of treatment services, fast-tracking the most immunodeficientpatients and improving access, especially for men.
Authors: Debbie Bradshaw; Pam Groenewald; Ria Laubscher; Nadine Nannan; Beatrice Nojilana; Rosana Norman; Desiréé Pieterse; Michelle Schneider; David E Bourne; Ian M Timaeus; Rob Dorrington; Leigh Johnson Journal: S Afr Med J Date: 2003-09
Authors: Jonathan A C Sterne; Ian R White; John B Carlin; Michael Spratt; Patrick Royston; Michael G Kenward; Angela M Wood; James R Carpenter Journal: BMJ Date: 2009-06-29
Authors: Edwin Wouters; Wim Van Damme; Francis Van Loon; Dingie van Rensburg; Herman Meulemans Journal: Soc Sci Med Date: 2009-08-18 Impact factor: 4.634
Authors: Abraham J Herbst; Graham S Cooke; Till Bärnighausen; Angelique KanyKany; Frank Tanser; Marie-Louise Newell Journal: Bull World Health Organ Date: 2009-10 Impact factor: 9.408
Authors: Lara R Fairall; Max O Bachmann; Goedele M C Louwagie; Cloete van Vuuren; Perpetual Chikobvu; Dewald Steyn; Gillian H Staniland; Venessa Timmerman; Mpumelelo Msimanga; Chris J Seebregts; Andrew Boulle; Ralph Nhiwatiwa; Eric D Bateman; Merrick F Zwarenstein; Ronald D Chapman Journal: Arch Intern Med Date: 2008-01-14
Authors: Suzanne M Ingle; Margaret May; Kerry Uebel; Venessa Timmerman; Eduan Kotze; Max Bachmann; Jonathan A C Sterne; Matthias Egger; Lara Fairall Journal: AIDS Date: 2010-11-13 Impact factor: 4.177
Authors: Neil Orr; Helen Hajiyiannis; Laura Myers; Mzamani Benjamin Makhubele; Tselisehang Matekane; Richard Delate; Lusanda Mahlasela; Brenda Goldblatt Journal: J Acquir Immune Defic Syndr Date: 2017-01-01 Impact factor: 3.731
Authors: Godfather Dickson Kimaro; Sayoki Mfinanga; Victoria Simms; Sokoine Kivuyo; Christian Bottomley; Neil Hawkins; Thomas S Harrison; Shabbar Jaffar; Lorna Guinness Journal: PLoS One Date: 2017-02-24 Impact factor: 3.240
Authors: Elizabeth du Toit; Cari van Schalkwyk; Rory Dunbar; Karen Jennings; Blia Yang; David Coetzee; Nulda Beyers Journal: PLoS One Date: 2014-05-07 Impact factor: 3.240